Power Law company profile

LianBio

Biotech & Life Sciences · Pudong, China · Founded 2019 · IPO 2021 Unicorn

Focused on bringing paradigm-shifting medicines to patients

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

14 investors on LianBio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 14 investors entered at this stage

BlackRock

Perceptive Advisors

T. Rowe Price

RA Capital Management

Wellington Management

Pfizer

Farallon Capital Management

Casdin Capital

Vida Ventures

Venrock

Sphera Funds Management

Viking Global Investors

Logos Capital

Tybourne Capital Management

Global footprint

Where LianBio has talent and traffic

Workforce by country

5 countries with
team presence

🇨🇳 China86%

🇸🇬 Singapore6.2%

🇺🇸 United States4.1%

🇬🇧 United Kingdom3.1%

🇹🇼 Taiwan2.9%

5 countries shown

Web traffic by country

51K monthly visits
across markets

🇪🇬 Egypt54.9%

🇩🇿 Algeria20.2%

🇩🇰 Denmark9.8%

🇲🇦 Morocco5.1%

🇱🇰 Sri Lanka4.5%

Top 5 markets shown

Market sentiment

What the market is saying about LianBio

An AI-synthesized read of the highest-engagement posts about LianBio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See LianBio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles